Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MA · listed Aug 18, 2009 → Mar 24, 2025
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:57 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
3 of 47 offerings report sales commissions totalling $7,073,558; 2 report finder's fees totalling $1,191,137; 4 report proceeds to related persons totalling $5,462,507. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 24, 2025 D File 021-541925 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 4, 2024 D File 021-523129 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 24, 2023 D File 021-498049 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 24, 2023 D File 021-498050 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 9, 2022 D File 021-458444 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 9, 2022 D File 021-458499 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 7, 2021 D File 021-385495 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 15, 2019 D File 021-339616 | $3,750,000 (est.) | $0 | $0 | Goldman Sachs & Co. LLC BrokerCheck CRD 361 ↗ |
| EDGAR ↗ | Apr 24, 2019 D File 021-337965 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 25, 2018 D File 021-313322 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 11, 2018 D/A File 021-282443 | $2,241,721 (est.) | $0 | $0 | Goldman, Sachs & Co. BrokerCheck CRD 361 ↗ ABG, LLC BrokerCheck CRD 167190 ↗ |
| EDGAR ↗ | Nov 15, 2017 D File 021-298744 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 13, 2017 D File 021-294605 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2016 D File 021-265295 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 17, 2016 D File 021-265322 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 28, 2016 D File 021-262245 | $1,081,837 | $11,737 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ Brookline Capital Markets BrokerCheck CRD 153587 ↗ M.M. Dillon & Co. Group BrokerCheck CRD 19878 ↗ |
| EDGAR ↗ | Aug 10, 2015 D File 021-245356 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 4, 2015 D File 021-245081 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 19, 2015 D File 021-234296 | $0 | $0 | $1,260,000 (est.) Estimated salary to named executive officers for calendar year 2015. | None listed on this filing |
| EDGAR ↗ | Oct 29, 2014 D File 021-227268 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2014 D File 021-225555 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 24, 2014 D File 021-221679 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes. | None listed on this filing |
| EDGAR ↗ | Mar 18, 2014 D File 021-213802 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 21, 2014 D/A File 021-192402 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 20, 2013 D/A File 021-186287 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 11, 2013 D File 021-191627 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 10, 2013 D/A File 021-184482 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jan 2, 2013 D File 021-189231 | $0 | $1,179,400 | $0 (est.) | William J. Kridel BrokerCheck CRD 704171 ↗ via FERGHANA SECURITIES, INC. (CRD 43430 ↗) E. Hunterson Herie BrokerCheck CRD 2431896 ↗ via FERGHANA SECURITIES, INC. (CRD 43430 ↗) A. Rawle Michelson BrokerCheck CRD 1507251 ↗ via FERGHANA SECURITIES, INC. (CRD 43430 ↗) |
| EDGAR ↗ | Dec 20, 2012 D/A File 021-154368 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 27, 2012 D File 021-187468 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 31, 2012 D File 021-183494 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes including, but not limited to, executive salaries. | None listed on this filing |
| EDGAR ↗ | Apr 20, 2012 D File 021-177000 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 15, 2011 D File 021-168716 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 3, 2011 D File 021-168180 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 20, 2011 D File 021-166104 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 20, 2011 D File 021-161480 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 11, 2011 D/A File 021-150610 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2011 D File 021-156088 | $0 | $0 | $2,279,507 (est.) This estimate excludes amounts paid and that may be paid to the law firm which two executive officers were/are affiliated. | None listed on this filing |
| EDGAR ↗ | Nov 16, 2010 D File 021-150608 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 21, 2010 D File 021-149416 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 16, 2010 D File 021-147844 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2010 D File 021-144770 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 7, 2010 D/A File 021-77621 | $0 | $0 | $1,200,000 (est.) This estimate excludes amounts paid and that may be paid to the law firms with which one of the executive officers was or is affiliated. | None listed on this filing |
| EDGAR ↗ | Jun 18, 2010 D File 021-143695 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2010 D File 021-142039 | $0 | $0 | $723,000 (est.) This estimate excludes amounts paid and that may be paid to the law firm which two executive officers were/are affiliated and also excludes amounts previously received from the issuance of convertible promissory notes that were converted in the financing. | None listed on this filing |
| EDGAR ↗ | Oct 13, 2009 D/A File 021-77391 | $0 | $0 | $0 (est.) Customary working capital purposes | None listed on this filing |
| EDGAR ↗ | Sep 25, 2009 D File 021-126495 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Octave Bioscience Inc | Director | Mar 24, 2025 | D | $53,674,121 similar: $829,831–$9,999,998 | $31,840,355 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Arsenal Biosciences, Inc. | Director | Sep 4, 2024 | D | $325,352,578 similar: $2,000,000–$19,999,994 | $325,352,578 | 26 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Octave Bioscience Inc | Director | Nov 24, 2023 | D | $6,999,999 similar: $829,831–$9,999,998 | $6,999,999 | 2 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Octave Bioscience Inc | Director | Nov 24, 2023 | D | $37,505,524 similar: $829,831–$9,999,998 | $32,500,070 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Arsenal Biosciences, Inc. | Director | Sep 9, 2022 | D | $230,806,614 similar: $2,000,000–$19,999,994 | $220,806,682 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Arsenal Biosciences, Inc. | Director | Sep 9, 2022 | D | $32,999,954 similar: $2,000,000–$19,999,994 | $32,999,954 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Octave Bioscience Inc | Director | Jan 7, 2021 | D | $32,000,000 similar: $829,831–$9,999,998 | $32,000,000 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Enjoy Technology, Inc. | Director | May 15, 2019 | D | $149,999,996 similar: $1,100,015–$10,001,163 | $74,999,996 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Epiodyne, Inc. | Director | Apr 24, 2019 | D | $7,999,997 similar: $2,000,000–$19,999,994 | $7,999,997 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GRAIL, Inc. | Director | May 25, 2018 | D | Indefinite similar: $2,000,000–$19,999,994 | $300,000,000 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GRAIL, Inc. | Director | Jan 11, 2018 | D/A | Indefinite similar: $2,000,000–$14,000,000 | $1,214,655,040 | 59 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GRAIL, Inc. | Director | Nov 22, 2017 | D/A | Indefinite similar: $2,000,000–$14,000,000 | $1,211,655,039 | 58 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Epiodyne, Inc. | Director | Nov 15, 2017 | D | $10,090,340 similar: $2,000,000–$19,999,994 | $5,780,340 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Octave Bioscience Inc | Director | Sep 13, 2017 | D | $2,500,000 similar: $829,831–$9,999,998 | $2,500,000 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | GRAIL, Inc. | Director | Apr 26, 2017 | D/A | Indefinite similar: $2,000,000–$14,000,000 | $973,248,965 | 47 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cell Design Labs, Inc. | Director | Jun 17, 2016 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cell Design Labs, Inc. | Director | Jun 17, 2016 | D | $22,890,007 similar: $2,000,000–$19,999,994 | $22,890,007 | 15 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CareDx, Inc. | Director | Apr 28, 2016 | D | $36,802,008 similar: $2,000,000–$19,999,994 | $14,169,129 | 39 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zephyr Health, Inc. | Director | Aug 10, 2015 | D | $19,999,995 similar: $829,831–$9,999,998 | $17,477,051 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Enjoy Technology, Inc. | Director | Aug 4, 2015 | D | $49,999,999 similar: $1,100,015–$10,001,163 | $49,999,999 | 12 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Director | Feb 19, 2015 | D | $9,000,000 similar: $2,000,000–$19,999,994 | $5,823,326 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Enjoy Technology, Inc. | Director | Oct 29, 2014 | D | $26,499,996 similar: $1,100,015–$10,001,163 | $26,499,996 | 8 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | VERACYTE, INC. | Director | Sep 30, 2014 | D | $12,797,283 similar: $829,831–$9,999,998 | $12,797,283 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | CARDIODX INC | Director | Jul 24, 2014 | D | $24,999,996 similar: $2,000,000–$14,000,000 | $20,983,348 | 14 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oculeve, Inc. | Director | Mar 18, 2014 | D | $16,649,997 similar: $829,831–$9,999,998 | $16,649,997 | 8 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Director | Feb 21, 2014 | D/A | $24,720,101 similar: $2,000,000–$19,999,994 | $24,720,101 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Oculeve, Inc. | Director | Mar 20, 2013 | D/A | $7,592,976 similar: $829,831–$9,999,998 | $7,590,476 | 9 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Executive Officer, Director | Feb 26, 2013 | D | $20,000,006 similar: $2,000,000–$19,999,994 | $12,000,002 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Director | Feb 11, 2013 | D | $20,500,000 similar: $1,100,015–$10,001,163 | $20,500,000 | 4 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Foundation Medicine, Inc. | Director | Jan 10, 2013 | D/A | $55,962,423 similar: $2,000,000–$19,999,994 | $55,962,423 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Jan 2, 2013 | D | $28,454,396 similar: $2,000,000–$19,999,994 | $28,454,396 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Executive Officer, Director | Dec 20, 2012 | D/A | $21,125,008 similar: $2,000,000–$19,999,994 | $21,125,008 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OptiMedica Corp | Director | Nov 27, 2012 | D | $35,000,001 similar: $829,831–$9,999,998 | $35,000,001 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Oculeve, Inc. | Director | Oct 30, 2012 | D | $7,565,476 similar: $829,831–$9,999,998 | $7,565,476 | 8 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Foundation Medicine, Inc. | Director | Sep 21, 2012 | D | $42,499,987 similar: $2,000,000–$19,999,994 | $42,499,987 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CARDIODX INC | Director | Aug 31, 2012 | D | $58,018,795 similar: $2,000,000–$19,999,994 | $30,509,397 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Executive Officer, Director | Aug 13, 2012 | D/A | $18,125,014 similar: $2,000,000–$19,999,994 | $18,125,014 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Apr 20, 2012 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CareDx, Inc. | Director | Nov 15, 2011 | D | $2,928,943 similar: $2,000,000–$19,999,994 | $2,155,781 | 31 similar: 2–16 | $1 similar: $10,000–$50,000 |
| EDGAR ↗ | KPCB China Fund II, L.P. group: Kleiner Perkins Caufield | Director | Nov 3, 2011 | D | $250,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Sep 20, 2011 | D | $25,000,000 similar: $2,000,000–$19,999,994 | $25,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Jun 20, 2011 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $31,019,775 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Elcelyx Therapeutics, Inc. | Director | May 10, 2011 | D/A | $14,125,007 similar: $2,000,000–$19,999,994 | $14,125,007 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KPCB Digital Growth Fund, LLC group: Kleiner Perkins Caufield | Executive Officer Managing Member | Mar 11, 2011 | D/A | $1,000,000,000 similar: $155,000–$5,250,000 | $932,326,251 | 158 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CARDIODX INC | Director | Mar 2, 2011 | D | $78,325,737 similar: $2,000,000–$19,999,994 | $57,491,448 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KPCB Digital Growth Fund, LLC group: Kleiner Perkins Caufield | Executive Officer Managing Member | Nov 16, 2010 | D | $750,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Kleiner Perkins Caufield & Byers XIV, LLC group: Kleiner Perkins Caufield | Executive Officer Managing Member | Nov 16, 2010 | D | $650,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | KPCB sFund, LLC group: Kleiner Perkins Caufield | Executive Officer Managing Member | Oct 21, 2010 | D | $50,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | FIVE PRIME THERAPEUTICS INC | Director | Sep 16, 2010 | D | $7,499,999 similar: $2,000,000–$19,999,994 | $7,499,999 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CareDx, Inc. | Director | Jul 12, 2010 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $6,041,511 | 48 similar: 2–16 | $1 similar: $10,000–$50,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Jul 7, 2010 | D/A | $42,600,004 similar: $2,000,000–$19,999,994 | $37,600,003 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VERACYTE, INC. | Director | Jun 18, 2010 | D | $28,435,000 similar: $2,000,000–$19,999,994 | $9,311,668 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CARDIODX INC | Director | May 14, 2010 | D | $44,536,736 similar: $2,000,000–$19,999,994 | $34,564,513 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Dec 23, 2009 | D/A | $27,600,001 similar: $2,000,000–$19,999,994 | $27,600,001 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Crescendo Bioscience, Inc. | Director | Nov 20, 2009 | D/A | $20,099,999 similar: $2,000,000–$19,999,994 | $20,099,999 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OptiMedica Corp | Director | Oct 13, 2009 | D/A | $35,035,000 similar: $829,831–$9,999,998 | $30,235,886 | 22 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | HX DIAGNOSTICS INC | Director | Sep 25, 2009 | D | $4,650,674 similar: $829,831–$9,999,998 | $4,650,674 | 2 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OptiMedica Corp | Director | Aug 18, 2009 | D | $35,035,000 similar: $829,831–$9,999,998 | $25,035,000 | 17 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (5 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Brook Byers. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Brook Byers appears on a new Form D, or when a court case or SEC action is matched to them. See plans →